Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 3;11(11):2968.
doi: 10.3390/biomedicines11112968.

Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes

Edyta Sutkowska  1 , Izabela Fecka  2   3 , Dominik Marciniak  4 , Katarzyna Bednarska  2 , Magdalena Sutkowska  5 , Katarzyna Hap  1
Affiliations

Analysis of Methylglyoxal Concentration in a Group of Patients with Newly Diagnosed Prediabetes

Edyta Sutkowska et al. Biomedicines. .

Abstract

Background: The abnormal serum concentration of methylglyoxal (MGO) has been presented as an indicator of chronic complications in diabetes (DM). Because such complications are also found in pre-DM, we decided to assess the concentration of this compound in individuals with pre-DM, without cardio-vascular diseases.

Methods: Frozen samples from individuals newly diagnosed with pre-DM (N = 31) and healthy subjects (N = 11) were prepared and MGO concentration was determined using UHPLC-ESI-QqTOF-MS.

Results: Statistical significance was established when the groups were compared for body weight, BMI, fasting glucose level, fatty liver and use of statins but not for the other descriptive parameters. The positive linear correlation showed that the higher HbA1c, the higher MGO concentration (p = 0.01). The values of MGO were within the normal range in both groups (mean value for pre-DM: 135.44 nM (±SD = 32.67) and for the control group: 143.25 nM (±SD = 17.93); p = 0.46 (±95% CI)), with no statistical significance between the groups.

Conclusions: We did not confirm the elevated MGO levels in the group of patients with pre-DM. The available data suggests a possible effect of statin intake on MGO levels. This thesis requires confirmation on a larger number of patients with an assessment of MGO levels before and after the introduction of statins.

Keywords: advanced glycation end-products; diabetic chronic complications; methylglyoxal; prediabetes.

PubMed Disclaimer

Conflict of interest statement

The principal researcher, E.S., was a lecturer for the following companies: AstraZeneca, Sanofi, NovoNordisk, Merck, Boehringer Ingelheim, and Mundipharma. For other authors, there are no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Linear correlation for HbA1c (glycated haemoglobin).
Figure 2
Figure 2
Linear correlation for TG (triglycerides).
Figure 3
Figure 3
Linear correlation for FPGl (fasting plasma glucose level).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. [(accessed on 1 July 2023)]. Available online: https://www.idf.org/metabolic_syndrome.
    1. Tuomilehto J., Wolf E. Primary prevention of diabetes mellitus. Diabetes Care. 1987;10:238–248. doi: 10.2337/diacare.10.2.238. - DOI - PubMed
    1. Roberts S., Barry E., Craig D., Airoldi M., Bevan G., Greenhalgh T. Preventing type 2 diabetes: Systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017;7:e017184. doi: 10.1136/bmjopen-2017-017184. - DOI - PMC - PubMed
    1. Aroda V.R., Knowler W.C., Crandall J.P., Perreault L., Edelstein S.L., Jeffries S.L., Molitch M.E., Pi-Sunyer X., Darwin C., Heckman-Stoddard B.M., et al. Metformin for diabetes prevention: Insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60:1601–1611. doi: 10.1007/s00125-017-4361-9. - DOI - PMC - PubMed
    1. Zhou X., Siegel K.R., Ng B.P., Jawanda S., Proia K.K., Zhang X., Albright A.L., Zhang P. Cost-effectiveness of diabetes prevention interventions targeting high-risk individuals and whole populations: A systematic review. Diabetes Care. 2020;43:1593–1616. doi: 10.2337/dci20-0018. - DOI - PubMed

LinkOut - more resources